Table 3.

Radiomics versus clinical outcome in third-line treatment

Third-line treatment group
	Treatment benefit					Progression-free survival				Overall survival
	Yes		No		p	HR	95% CI		p	HR	95% CI		p
	Mean	SD	Mean	SD			Lower	Upper			Lower	Upper
Mean SUVmax	7.71	2.30	9.27	4.00	0.10	1.11	0.96	1.27	0.16	1.19	1.01	1.41	0.03*
Mean SUVpeak	6.42	1.84	7.36	3.00	0.20	1.11	0.96	1.29	0.15	1.21	1.01	1.45	0.04*
Mean SUVmean	4.81	1.45	5.53	1.76	0.16	1.07	0.95	1.20	0.27	1.11	0.97	1.28	0.15
Mean compactness	0.03	0.01	0.03	0.01	0.12	0.90	0.78	1.04	0.16	0.88	0.74	1.05	0.15
Mean sphericity	0.71	0.16	0.61	0.21	0.10	0.90	0.78	1.04	0.17	0.88	0.74	1.05	0.15
Mean AUC-CSH	0.68	0.10	0.71	0.05	0.28	0.92	0.81	1.03	0.16	0.93	0.82	1.05	0.23
Mean entropy	5.35	0.17	5.31	0.22	0.48	1.00	0.91	1.10	0.98	0.96	0.86	1.07	0.45
Mean entropy FXD	3.61	0.63	4.00	0.64	0.07	1.03	0.91	1.16	0.69	1.07	0.94	1.22	0.31
Mean MATV	32.54	95.33	30.34	90.98	0.81	1.27	1.05	1.54	0.02*	1.68	1.20	2.37	<0.01*
SUM MATV	160.33	289.30	156.77	160.88	0.71	1.35	1.09	1.68	0.01*	2.04	1.36	3.07	<0.01*
Mean TLG	187.26	471.51	175.13	615.03	0.71	1.29	1.06	1.56	0.01*	1.54	1.15	2.05	<0.01*
SUM TLG	773.33	1540.94	841.75	812.74	0.51	1.27	1.06	1.53	0.01*	1.80	1.24	2.61	<0.01*